STAT19h
Trump’s FDA navigates layoffs, exits, and a new hire
The Trump administration has started rehiring some of the FDA employees it fired last week, the latest chapter in a haphazard ...
BioSpace3h
How SpringWorks Took Pfizer’s Rare Disease Ghost Drug and Got It to Patients
SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for ...
C&EN12d
FDA approves drug for neurofibromatosis
Pfizer had shelved the drug after it appeared that AstraZeneca would beat it to market with a competing drug. But mirdametinib still held value to the NF1 community, so the Children’s Tumor ...
Peninsula drugmaker nails heart failure drug launch in battle with Big Pharma
But the direct-to-consumer ad didn't come from Palo Alto-based Bridge Bio (Nasdaq: BBIO); instead it was produced by Pfizer ...
Pfizer stops commercialization of hemophilia gene therapy Beqvez
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...
BioPharma Dive2d
Summit partners with Pfizer to study bispecific, ADC combinations
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
STAT2d
Pfizer CEO Albert Bourla inflicts injury on his company — and all of pharma
The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...